Neuromusculoskeletal Modeling of Muscle Spasticity
Launched by REGION STOCKHOLM · Jul 1, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
How long-term standard treatments for children with spastic cerebral palsy (CP), including training and orthotics use, with botulinum toxin (BoNT-A) treatment as an adjunct, affects muscle on functional, structural, and microscopic level in CP has not yet been published. Therefore, we will investigate the muscle function as well as functional mobility, structure, and spasticity.
Research questions:
* How is muscle structure, muscle strength, spasticity and, stiffness of the calf muscle in CP related to motor function, and how does it differ to typically developing (TD) children?
* What is...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Unilateral/Bilateral spastic CP without Botulinum toxin injection history
- • Understanding study protocol and expressing voluntary consent of the family
- • Dorsiflexion to at least a neutral position of the foot
- Exclusion Criteria:
- • Contraindication to MRI scanning: metal fragments in the body, surgically implanted devices containing metal, severe claustrophobia, or inability to lie down in the MRI scanner, presence of pacemaker or other stimulators, shunts etc.
- • Total range of ankle movement less than 35°
About Region Stockholm
Region Stockholm is a leading healthcare authority committed to advancing medical research and improving patient care through innovative clinical trials. As a sponsor, Region Stockholm collaborates with hospitals, research institutions, and industry partners to facilitate the development of new therapies and treatment protocols. With a focus on quality, safety, and ethical standards, the organization aims to enhance health outcomes for the diverse population of Stockholm and beyond, leveraging cutting-edge research to translate scientific discoveries into effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
R Wang, Ing, PhD
Principal Investigator
KTH Royal Institute of Technology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials